• Events
    • EURETINA 2024 Barcelona
      • Programme Submission Terms
      • Submit Programme Abstract
    • EURETINA 2023 Amsterdam
      • Amsterdam On Demand
      • Congress Daily
      • Congress Photo Gallery
      • Information
      • Programme
      • Abstracts
      • Late Breaking
      • Hotels
      • Registration
      • Exhibition Bookings
      • EURETINA Innovation Spotlight (EIS)
    • EURETINA Innovation Spotlight (EIS)
      • Information
      • Programme
      • Contributors
      • Registration
      • Sponsorship
      • Industry Abstracts
    • EURETINA 2023 Vilnius (Winter Meeting)
      • Information
      • Programme
      • Hotels
      • Exhibition Information
      • Abstract Viewer
    • EURETINA 2022 Hamburg
      • On Demand
      • Sustainability Plan
      • Programme Overview
      • Satellite Symposia
      • Exhibitors
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Abstract Viewer
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Committees
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • EBO-Euretina Exam
    • Mentorship Programme
    • RMCR Grant Programme
    • Observership Grant Programme
    • Women in Retina
      • Seeing is Believing Collection
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • EURETINA 2024 Barcelona
      • Programme Submission Terms
      • Submit Programme Abstract
    • EURETINA 2023 Amsterdam
      • Amsterdam On Demand
      • Congress Daily
      • Congress Photo Gallery
      • Information
      • Programme
      • Abstracts
      • Late Breaking
      • Hotels
      • Registration
      • Exhibition Bookings
      • EURETINA Innovation Spotlight (EIS)
    • EURETINA Innovation Spotlight (EIS)
      • Information
      • Programme
      • Contributors
      • Registration
      • Sponsorship
      • Industry Abstracts
    • EURETINA 2023 Vilnius (Winter Meeting)
      • Information
      • Programme
      • Hotels
      • Exhibition Information
      • Abstract Viewer
    • EURETINA 2022 Hamburg
      • On Demand
      • Sustainability Plan
      • Programme Overview
      • Satellite Symposia
      • Exhibitors
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Abstract Viewer
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Committees
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • EBO-Euretina Exam
    • Mentorship Programme
    • RMCR Grant Programme
    • Observership Grant Programme
    • Women in Retina
      • Seeing is Believing Collection
    • YOURS
    • CME Credits
  • Member Login
  • August 23, 2020
  • Author: EURETINA Brief

Five year outcome data is reported for 3 anti-VEGF treatments in diabetic macular edema

Clinical researchers at the Jaeb Center for Health Research, Tampa, Florida and the Beetham Eye Institute, Harvard in Boston, (supported by the DRCR Retina Network) have reported results for long-term outcomes for eyes with visual impairment from CI-DME (center-involved diabetic macular edema).  From an extension study after 5 years, mean visual acuity (VA) improved from baseline by 7.4 letters but decreased by 4.7 letters between 2 and 5 years.  The DRCR Retina Network had conducted a randomized clinical trial (Protocol T) comparing aflibercept, bevacizumab and ranibizumab.  Regardless, Dr. Thomas Ciulla, from the Indiana University School of Medical School in Indianapolis, commented that “the fact that these patients retained a reasonable improvement over 5 years is quite remarkable.  The doctors involved in caring for these patients and the clinical investigators should be commended”.

 

The DRCR Retina Network had previously reported a protocol retreatment regimen for 2 years showing that results demonstrated improved mean VA using anti-VEGF treatment.  When baseline VA impairment was mild (20/32-20/40), there were no apparent differences between agents for mean change in VA from baseline at 1 year (primary outcome) or 2 years. However, when baseline VA impairment was more severe (20/50-20/320), aflibercept was superior to both bevacizumab and ranibizumab at 1 year and bevacizumabat 2 years. Protocol T ended after 2 years of protocol-defined retreatment regimens. Participants were asked to return at 5 years from randomization to assess clinical outcomes and characterize follow-up treatments for DME and diabetic retinopathy (DR).  During Protocol T, visits were scheduled every 4 weeks in year 1 and every 4 to 16 weeks in year 2, depending on treatment response. After Protocol T participation concluded at 2 years, follow-up and treatment were performed as standard care.

 

At the most recent follow-up outcomes, results have reported that sixty-eight percent (317/463) of eligible participants completed the 5-year visit. Between years 2 and 5, 68% (217/317) of study eyes received at least 1 anti-VEGF treatment (median, 4; interquartile range [IQR], 0-12). At 5 years, mean VA improved from baseline by 7.4 letters (95% confidence interval [CI], 5.9-9.0) but decreased by 4.7 letters (95% CI, 3.3-6.0) between 2 and 5 years. When baseline VA was 20/50 to 20/320, mean 5-year VA was 11.9 letters (95% CI, 9.3-14.5) better than baseline but 4.8 letters (95% CI, 2.5-7.0) worse than 2 years. When baseline VA was 20/32 to 20/40, mean 5-year VA was 3.2 letters (95% CI, 1.4-5.0) better than baseline but 4.6 letters (95% CI, 3.1-6.1) worse than 2 years. Mean CST decreased from baseline to 5 years by 154 μm (95% CI, 142-166) and was stable between 2 and 5 years (-1 μm; 95% CI, -12 to 9).  In conclusion from the study, the researchers commented that, “of among the approximately two-thirds of eligible Protocol T participants who completed a 5-year visit, mean VA improved from baseline to 5 years with no protocol defined visit schedule or treatment protocol after study follow-up ended at 2 years. Although there were no substantial differences in mean retinal thickness at 2 and 5 years, mean VA decreased during this time”.

PrevPrevious
NextNext

Meet the Keynote Speakers

Euretina Lecture with Sobha Sivaprasad
Opthalmologica Lecture with Enrico Borrelli
Ophthalmologica Lecture with Enrico Borrelli
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Kreissig Award Lecture with Hiroko Terasaki
Kreissig Award Lecture with Hiroko Terasaki

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2023 Amsterdam

EURETINA Innovation Spotlight (EIS)

Abstract Viewer

Ophthalmologica

Forum

Opportunities

Memberships

About

Privacy Policy

Contact Us

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2023 All rights reserved

  • Events
    • EURETINA 2024 Barcelona
      • Programme Submission Terms
      • Submit Programme Abstract
    • EURETINA 2023 Amsterdam
      • Amsterdam On Demand
      • Congress Daily
      • Congress Photo Gallery
      • Information
      • Programme
      • Abstracts
      • Late Breaking
      • Hotels
      • Registration
      • Exhibition Bookings
      • EURETINA Innovation Spotlight (EIS)
    • EURETINA Innovation Spotlight (EIS)
      • Information
      • Programme
      • Contributors
      • Registration
      • Sponsorship
      • Industry Abstracts
    • EURETINA 2023 Vilnius (Winter Meeting)
      • Information
      • Programme
      • Hotels
      • Exhibition Information
      • Abstract Viewer
    • EURETINA 2022 Hamburg
      • On Demand
      • Sustainability Plan
      • Programme Overview
      • Satellite Symposia
      • Exhibitors
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Abstract Viewer
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Committees
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • EBO-Euretina Exam
    • Mentorship Programme
    • RMCR Grant Programme
    • Observership Grant Programme
    • Women in Retina
      • Seeing is Believing Collection
    • YOURS
    • CME Credits
  • Member Login